_version_ 1783659999475531776
author Zlotoff, Daniel A
Hassan, Malek Z O
Zafar, Amna
Alvi, Raza M
Awadalla, Magid
Mahmood, Syed S
Zhang, Lili
Chen, Carol L
Ederhy, Stephane
Barac, Ana
Banerji, Dahlia
Jones-O'Connor, Maeve
Murphy, Sean P
Armanious, Merna
Forrestal, Brian J
Kirchberger, Michael C
Coelho-Filho, Otavio R
Rizvi, Muhammad A
Sahni, Gagan
Mandawat, Anant
Tocchetti, Carlo G
Hartmann, Sarah
Gilman, Hannah K
Zatarain-Nicolás, Eduardo
Mahmoudi, Michael
Gupta, Dipti
Sullivan, Ryan
Ganatra, Sarju
Yang, Eric H
Heinzerling, Lucie M
Thuny, Franck
Zubiri, Leyre
Reynolds, Kerry L
Cohen, Justine V
Lyon, Alexander R
Groarke, John
Thavendiranathan, Paaladinesh
Nohria, Anju
Fradley, Michael G
Neilan, Tomas G
author_facet Zlotoff, Daniel A
Hassan, Malek Z O
Zafar, Amna
Alvi, Raza M
Awadalla, Magid
Mahmood, Syed S
Zhang, Lili
Chen, Carol L
Ederhy, Stephane
Barac, Ana
Banerji, Dahlia
Jones-O'Connor, Maeve
Murphy, Sean P
Armanious, Merna
Forrestal, Brian J
Kirchberger, Michael C
Coelho-Filho, Otavio R
Rizvi, Muhammad A
Sahni, Gagan
Mandawat, Anant
Tocchetti, Carlo G
Hartmann, Sarah
Gilman, Hannah K
Zatarain-Nicolás, Eduardo
Mahmoudi, Michael
Gupta, Dipti
Sullivan, Ryan
Ganatra, Sarju
Yang, Eric H
Heinzerling, Lucie M
Thuny, Franck
Zubiri, Leyre
Reynolds, Kerry L
Cohen, Justine V
Lyon, Alexander R
Groarke, John
Thavendiranathan, Paaladinesh
Nohria, Anju
Fradley, Michael G
Neilan, Tomas G
author_sort Zlotoff, Daniel A
collection PubMed
description BACKGROUND: Myocarditis is a highly morbid complication of immune checkpoint inhibitor (ICI) use that remains inadequately characterized. The QRS duration and the QTc interval are standardized electrocardiographic measures that are prolonged in other cardiac conditions; however, there are no data on their utility in ICI myocarditis. METHODS: From an international registry, ECG parameters were compared between 140 myocarditis cases and 179 controls across multiple time points (pre-ICI, on ICI prior to myocarditis, and at the time of myocarditis). The association between ECG values and major adverse cardiac events (MACE) was also tested. RESULTS: Both the QRS duration and QTc interval were similar between cases and controls prior to myocarditis. When compared with controls on an ICI (93±19 ms) or to baseline prior to myocarditis (97±19 ms), the QRS duration prolonged with myocarditis (110±22 ms, p<0.001 and p=0.009, respectively). In contrast, the QTc interval at the time of myocarditis (435±39 ms) was not increased compared with pre-myocarditis baseline (422±27 ms, p=0.42). A prolonged QRS duration conferred an increased risk of subsequent MACE (HR 3.28, 95% CI 1.98 to 5.62, p<0.001). After adjustment, each 10 ms increase in the QRS duration conferred a 1.3-fold increase in the odds of MACE (95% CI 1.07 to 1.61, p=0.011). Conversely, there was no association between the QTc interval and MACE among men (HR 1.33, 95% CI 0.70 to 2.53, p=0.38) or women (HR 1.48, 95% CI 0.61 to 3.58, p=0.39). CONCLUSIONS: The QRS duration is increased in ICI myocarditis and is associated with increased MACE risk. Use of this widely available ECG parameter may aid in ICI myocarditis diagnosis and risk-stratification.
format Online
Article
Text
id pubmed-7929895
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-79298952021-03-19 Electrocardiographic features of immune checkpoint inhibitor associated myocarditis Zlotoff, Daniel A Hassan, Malek Z O Zafar, Amna Alvi, Raza M Awadalla, Magid Mahmood, Syed S Zhang, Lili Chen, Carol L Ederhy, Stephane Barac, Ana Banerji, Dahlia Jones-O'Connor, Maeve Murphy, Sean P Armanious, Merna Forrestal, Brian J Kirchberger, Michael C Coelho-Filho, Otavio R Rizvi, Muhammad A Sahni, Gagan Mandawat, Anant Tocchetti, Carlo G Hartmann, Sarah Gilman, Hannah K Zatarain-Nicolás, Eduardo Mahmoudi, Michael Gupta, Dipti Sullivan, Ryan Ganatra, Sarju Yang, Eric H Heinzerling, Lucie M Thuny, Franck Zubiri, Leyre Reynolds, Kerry L Cohen, Justine V Lyon, Alexander R Groarke, John Thavendiranathan, Paaladinesh Nohria, Anju Fradley, Michael G Neilan, Tomas G J Immunother Cancer Clinical/Translational Cancer Immunotherapy BACKGROUND: Myocarditis is a highly morbid complication of immune checkpoint inhibitor (ICI) use that remains inadequately characterized. The QRS duration and the QTc interval are standardized electrocardiographic measures that are prolonged in other cardiac conditions; however, there are no data on their utility in ICI myocarditis. METHODS: From an international registry, ECG parameters were compared between 140 myocarditis cases and 179 controls across multiple time points (pre-ICI, on ICI prior to myocarditis, and at the time of myocarditis). The association between ECG values and major adverse cardiac events (MACE) was also tested. RESULTS: Both the QRS duration and QTc interval were similar between cases and controls prior to myocarditis. When compared with controls on an ICI (93±19 ms) or to baseline prior to myocarditis (97±19 ms), the QRS duration prolonged with myocarditis (110±22 ms, p<0.001 and p=0.009, respectively). In contrast, the QTc interval at the time of myocarditis (435±39 ms) was not increased compared with pre-myocarditis baseline (422±27 ms, p=0.42). A prolonged QRS duration conferred an increased risk of subsequent MACE (HR 3.28, 95% CI 1.98 to 5.62, p<0.001). After adjustment, each 10 ms increase in the QRS duration conferred a 1.3-fold increase in the odds of MACE (95% CI 1.07 to 1.61, p=0.011). Conversely, there was no association between the QTc interval and MACE among men (HR 1.33, 95% CI 0.70 to 2.53, p=0.38) or women (HR 1.48, 95% CI 0.61 to 3.58, p=0.39). CONCLUSIONS: The QRS duration is increased in ICI myocarditis and is associated with increased MACE risk. Use of this widely available ECG parameter may aid in ICI myocarditis diagnosis and risk-stratification. BMJ Publishing Group 2021-03-02 /pmc/articles/PMC7929895/ /pubmed/33653803 http://dx.doi.org/10.1136/jitc-2020-002007 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Clinical/Translational Cancer Immunotherapy
Zlotoff, Daniel A
Hassan, Malek Z O
Zafar, Amna
Alvi, Raza M
Awadalla, Magid
Mahmood, Syed S
Zhang, Lili
Chen, Carol L
Ederhy, Stephane
Barac, Ana
Banerji, Dahlia
Jones-O'Connor, Maeve
Murphy, Sean P
Armanious, Merna
Forrestal, Brian J
Kirchberger, Michael C
Coelho-Filho, Otavio R
Rizvi, Muhammad A
Sahni, Gagan
Mandawat, Anant
Tocchetti, Carlo G
Hartmann, Sarah
Gilman, Hannah K
Zatarain-Nicolás, Eduardo
Mahmoudi, Michael
Gupta, Dipti
Sullivan, Ryan
Ganatra, Sarju
Yang, Eric H
Heinzerling, Lucie M
Thuny, Franck
Zubiri, Leyre
Reynolds, Kerry L
Cohen, Justine V
Lyon, Alexander R
Groarke, John
Thavendiranathan, Paaladinesh
Nohria, Anju
Fradley, Michael G
Neilan, Tomas G
Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
title Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
title_full Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
title_fullStr Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
title_full_unstemmed Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
title_short Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
title_sort electrocardiographic features of immune checkpoint inhibitor associated myocarditis
topic Clinical/Translational Cancer Immunotherapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929895/
https://www.ncbi.nlm.nih.gov/pubmed/33653803
http://dx.doi.org/10.1136/jitc-2020-002007
work_keys_str_mv AT zlotoffdaniela electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT hassanmalekzo electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT zafaramna electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT alvirazam electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT awadallamagid electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT mahmoodsyeds electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT zhanglili electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT chencaroll electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT ederhystephane electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT baracana electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT banerjidahlia electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT jonesoconnormaeve electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT murphyseanp electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT armaniousmerna electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT forrestalbrianj electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT kirchbergermichaelc electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT coelhofilhootavior electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT rizvimuhammada electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT sahnigagan electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT mandawatanant electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT tocchetticarlog electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT hartmannsarah electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT gilmanhannahk electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT zatarainnicolaseduardo electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT mahmoudimichael electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT guptadipti electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT sullivanryan electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT ganatrasarju electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT yangerich electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT heinzerlingluciem electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT thunyfranck electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT zubirileyre electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT reynoldskerryl electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT cohenjustinev electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT lyonalexanderr electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT groarkejohn electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT thavendiranathanpaaladinesh electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT nohriaanju electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT fradleymichaelg electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis
AT neilantomasg electrocardiographicfeaturesofimmunecheckpointinhibitorassociatedmyocarditis